Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting

Table 3 Distribution of symptomatic drug (i.e., analgesics) dosage units among users

		T0	T6	T12	T18
NSAID use (total number of dosage units)	Mean ± SD Median (q1–q3) Range 95% CI Users	39.7 ± 31.3 30 (20–55) 3–120 30.6–49.5 27	11.8 ± 15.9 4 (3–15) 2–70 7.8–18.7 25	8.2 ± 9.0 4.5 (2.5–11.5) 1–40 4.7–13.2 28	5.4 ± 6.6 3 (2–6) 1–30 2.8–10.0 28
Triptan use (total number of dosage units)	Mean ± SD Median (q1–q3) Range 95% CI Users	30.4 ± 26.4 24 (15–30) 7–120 21.3–41.7 23	21.9 + 30.6 9 (5–22) 2–120 12.0–29.2 17	8.6 ± 9.5 5.5 (2.5–10) 1–35 4.4–16.1 20	7.6 ± 8.1 5 (3–9) 1–30 3.0–15.0 15
Other drugs use (total number of dosage units)	Mean ± SD Median (q1–q3) Range 95% CI Users	40.1 ± 37.0 30 (9–50) 3–120 28.2–54.0 18	11.9 ± 16.2 6 (3–12) 1–70 7.2–21.4 19	6.6 ± 6.7 4.5 (2.10) 1–30 4.2–15.5 22	5.1 ± 5.8 3 (2–6) 1–22 1.7–13.3 13
p values from HGLM and pairwise comparisons
Outcome	p for overall difference	T6 vs. T0	T12 vs. T6	T18 vs. T12	p for trend
NSAID use (total number of dosage units)	<0.001	<0.001	0.195	0.205	<0.001
Triptan use (total number of dosage units)	<0.001	0.015	0.005	0.483	<0.001
Other drugs use (total number of dosage units)	<0.001	<0.001	0.241	0.241	<0.001